132076-32-5 Usage
Description
Cyclopentanecarboxylic acid, 3-oxo-, methyl ester, (S)(9CI), also known as (S)-3-Oxo-cyclopentanecarboxylic acid methyl ester, is a synthetic intermediate that plays a crucial role in the pharmaceutical industry. It is an organic compound derived from cyclopentanecarboxylic acid, featuring a methyl ester group and a 3-oxo functional group. Cyclopentanecarboxylic acid, 3-oxo-, methyl ester, (S)(9CI) is known for its potential applications in the synthesis of various pharmaceutical compounds.
Uses
Used in Pharmaceutical Synthesis:
Cyclopentanecarboxylic acid, 3-oxo-, methyl ester, (S)(9CI) is used as a synthetic intermediate for the development of pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block in the synthesis of various drugs, particularly those targeting specific medical conditions.
Used in Drug Development:
In the pharmaceutical industry, Cyclopentanecarboxylic acid, 3-oxo-, methyl ester, (S)(9CI) is used as a key component in the development of new drugs. Its versatile structure allows for the creation of a wide range of drug candidates, which can be further modified and optimized to enhance their therapeutic properties.
Used in Medicinal Chemistry Research:
Cyclopentanecarboxylic acid, 3-oxo-, methyl ester, (S)(9CI) is also utilized in medicinal chemistry research to study the structure-activity relationships of various drug candidates. By understanding how this compound interacts with biological targets, researchers can design more effective and selective drugs with improved pharmacological profiles.
Used in Drug Delivery Systems:
In addition to its role in drug synthesis, Cyclopentanecarboxylic acid, 3-oxo-, methyl ester, (S)(9CI) can also be employed in the development of drug delivery systems. Its unique properties may allow for the creation of novel drug carriers that can improve the bioavailability, targeting, and overall efficacy of pharmaceutical compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 132076-32-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,0,7 and 6 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 132076-32:
(8*1)+(7*3)+(6*2)+(5*0)+(4*7)+(3*6)+(2*3)+(1*2)=95
95 % 10 = 5
So 132076-32-5 is a valid CAS Registry Number.
132076-32-5Relevant articles and documents
Asymmetric Synthesis of N-Substituted γ-Amino Esters and γ-Lactams Containing α,γ-Stereogenic Centers via a Stereoselective Enzymatic Cascade
Li, Ming,Cui, Yunfeng,Xu, Zefei,Chen, Xi,Feng, Jinhui,Wang, Min,Yao, Peiyuan,Wu, Qiaqing,Zhu, Dunming
, p. 372 - 379 (2021/10/25)
γ-Amino esters and γ-lactams containing α,γ-stereogenic centers are widely used as chiral intermediates in various bioactive compounds, while their efficient synthesis remains a challenge. Herein, an enzymatic cascade reaction involving an ene reductase (
Biocatalytic access to nonracemic γ-oxo esters: Via stereoselective reduction using ene-reductases
Turrini, Nikolaus G.,Cioc, Rǎzvan C.,Van Der Niet, Daan J. H.,Ruijter, Eelco,Orru, Romano V. A.,Hall, Mélanie,Faber, Kurt
, p. 511 - 518 (2017/08/14)
The asymmetric bioreduction of α,β-unsaturated γ-keto esters using ene-reductases from the Old Yellow Enzyme family proceeds with excellent stereoselectivity and high conversion levels, covering a broad range of acyclic and cyclic derivatives. Various strategies were employed to provide access to both enantiomers, which are versatile precursors of bioactive molecules. The regioselectivity of hydride addition on di-activated alkenes was elucidated by isotopic labeling experiments and showed strong preference for the keto moiety as activating/binding group as opposed to the ester. Finally, chemoenzymatic synthesis of (R)-2-(2-oxocyclohexyl)acetic acid was achieved in high ee on a preparative scale combining enzymatic reduction followed by ester hydrogenolysis.
2,2-DIFLUORODIOXOLO A2A RECEPTOR ANTAGONISTS
-
Page/Page column 87, (2015/03/16)
The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of A2A receptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which A2A receptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which A2A receptors are involved.
